To study the association of race and other patient characteristics associated with angiotensin converting enzyme (ACE) inhibitor-associated angioedema.
This was a retrospective cohort study of participants in the Tennessee Medicaid Program (=15 years of age) to whom ACE inhibitors had been prescribed from 1986 through 1992.
We identified 82 patients with confirmed angioedema during 51,752 person-years of ACE inhibitor use, giving an overall rate of angioedema of 1.6 per 1000 person-years of ACE inhibitor use.
After potential confounding factors were controlled for, the adjusted relative risk (RR) of angioedema among black American users of ACE inhibitors was 4.5 (95% confidence interval [CI] 2.9 to 6.8) compared with white subjects.
In addition to race, other factors associated with a significantly increased relative risk in the entire population were the first 30 days of ACE inhibitor use (RR, 4.6 ; 95% CI, 2.5 to 8.5) compared to>1 year of use, use of either lisinopril (RR, 2.2 ; 95% CI, 1.2 to 3.9) or enalapril (RR, 2.2 ; 95% CI, 1.4 to 3.5) compared to captopril, and previous hospitalization for any diagnosis within 30 days (RR, 2.0 ; 95% CI, 1.1 to 3.6).
Neither ACE inhibitor dose nor concurrent diuretic use was associated with the risk of angioedema. (...)
Mots-clés Pascal : Inhibiteur angiotensin converting enzyme, Antihypertenseur, Toxicité, Oedème angioneurotique, Facteur risque, Noir américain, Négroïde, Homme, Epidémiologie, Etats Unis, Amérique du Nord, Amérique, Pharmacogénétique, Génétique, Race, Allergie, Immunopathologie, Maladie héréditaire
Mots-clés Pascal anglais : ACE inhibitor, Antihypertensive agent, Toxicity, Angioneurotic edema, Risk factor, Black American, Negroid, Human, Epidemiology, United States, North America, America, Pharmacogenetics, Genetics, Race, Allergy, Immunopathology, Genetic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0389645
Code Inist : 002B02U10. Création : 10/04/1997.